GoserelinGnRH agonist implant
Goserelin first stimulates and then suppresses the pituitary GnRH system when exposure is sustained. Its medical uses rely on lowering sex-hormone activity in specific hormone-sensitive conditions.
What is Goserelin?
Goserelin is a GnRH agonist delivered as a sustained-release implant. It is used in defined hormone-dependent conditions, including prostate cancer, some breast-cancer settings and endometriosis. 1 2
How it works
Initial GnRH stimulation is followed by pituitary downregulation. This reduces LH and FSH signalling and lowers testosterone or oestrogen, depending on the treatment context. 2
Effects studied
Hormone-dependent disease control
Clinical effects depend on the diagnosis and accompanying treatment. For example, ZEBRA studied a particular breast-cancer population; it does not establish a universal replacement for chemotherapy.
Evidence: Indication-specific clinical trial and product information. 1 2
What does the evidence show?
Disease-specific trials and product-label lead
Why stimulation leads to suppression
GnRH normally arrives at the pituitary in pulses. Goserelin is an agonist delivered in a sustained-release implant. Continuous stimulation eventually reduces the system’s responsiveness, lowering the signals that drive testosterone or ovarian hormone production. The early phase can therefore differ from the intended longer-term effect.
Why this is useful in several conditions
Reducing sex-hormone stimulation can be relevant to selected prostate and breast cancers and to some non-cancer conditions such as endometriosis. These are distinct treatment pathways. A product’s indication, formulation and patient group must be specified rather than treating hormone suppression as a universal benefit.
What a cancer comparison can show
The retained ZEBRA study concerns a particular breast-cancer population and chemotherapy comparison. It cannot establish that goserelin replaces chemotherapy across breast cancers, whose biology and treatment needs differ. A result in one hormone-sensitive subgroup belongs to that subgroup. 1
Effects of sustained hormone suppression
Hot flushes, sexual symptoms and bone effects follow from lowering sex hormones; other risks depend on the condition and concomitant treatment. The implant also creates administration-related considerations. These effects are part of the treatment decision, not evidence that the medicine is unsuitable in every case. Its usefulness depends on a clearly defined clinical goal. 2
Safety & status
An initial hormonal flare can matter clinically. Longer-term suppression can affect bone health, sexual function and symptoms such as hot flushes; implant administration also has its own precautions. 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Why can an agonist eventually lower hormones?
Sustained stimulation causes the pituitary response to downregulate after the initial rise. 2
Does one cancer trial apply to every cancer use?
No. Tumour biology, disease stage and the surrounding treatment determine how the evidence applies. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Retained source reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.